ArticleTranslational cancer research2022
Leptomeningeal metastasis from
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 5 citations in OpenAlex.
- Article
- Leptomeningeal metastasis from large-cell neuroendocrine carcinoma of the cervix: a case report and literature review.Frontiers in oncology · 2026Article
- Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.Human vaccines & immunotherapeutics · 2023Article
- Isolated Intramedullary Spinal Cord Metastasis from Nasopharyngeal Carcinoma: A Case Report and Systematic Review.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leptomeningeal metastasis (LM) have a poor prognosis and rare studies have reported LM from nasopharyngeal carcinoma (NPC). Immune checkpoint inhibitor (ICI) was the standard first line treatment for metastatic NPC and was reported to improve intracranial response and survival in several types of cancer. Case Description: In this case presentation, we present a case of a 26-year-old man with Conclusions: This case highlights the diagnosis and treatment of LM from NPC, and provides an optional regimen after ICI failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.